Sign in Create account

Vineet Laboratories Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: VINEETLAB BSE: 543298
₹37.16
▲ 0.44 (1.20%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
26/100
Weak
Valuation
89/100
Undervalued
Momentum
68/100
Neutral

QVM read Cheap on its own multiples Quality Weak, Valuation Undervalued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹71 Cr
PE (TTM)
Data unavailable.
Price to Book
1.6
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
15.6
Relative return vs Sector, qtr %
11.7
Free Cash Flow
₹-13 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
114.86%
as of Dec. 31, 2025
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
0.00%
as of March 31, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-27.21%
as of March 31, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-176.23%
as of Dec. 31, 2024
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-13.54%
as of Dec. 31, 2025
Industry median 14.05% (173 companies)
Current Ratio
1.47
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.99
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
-1.28
as of March 31, 2026
Industry median 10.58 (182 companies)
Net Margin
-31.53%
as of Dec. 31, 2024
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
12.22%
as of Dec. 31, 2025
Industry median 14.22% (181 companies)
Operating Margin (TTM)
-11.25%
as of March 31, 2026
Industry median 12.41% (182 companies)
Return on Assets
-6.20%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
-10.68%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
-16.98%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

1 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Debt to equity is below 0.5 (0.99)
  • No Return on equity is 15% or more (-17.0%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

4 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

2 of 5 met
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
1.2%
Low 35.0000 · High 38.4900
1W return
6.7%
Low 34.1000 · High 38.4900
1M return
-4.4%
Low 34.1000 · High 39.0000
52W return
-12.0%
Low 27.9600 · High 49.9900
Lifetime High ₹119.4000 (July 9, 2021)
Lifetime Low ₹27.0100 (May 8, 2025)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish6
Bearish0
5D
36.2
10D
36.0
20D
36.3
50D
36.6
100D
36.1
200D
35.0

Delivery and volume

Day avg. delivery
95.4%
Week avg. delivery
92.7%
Month avg. delivery
83.9%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

36.88
Pivot
First resistance38.77
Second resistance40.37
Third resistance42.26
First support35.28
Second support33.39
Third support31.79
Day RSI54.5
Day MFI71.7
Day MACD-0.41
Day MACD signal-0.51

Beta

1M-0.12
3M-0.17
1Y0.53
3Y0.86

Price change analysis

↓ -4.4%
Over 1 Month
LowHigh
34.1039.00
↑ 11.7%
Over 3 Months
LowHigh
31.5040.20
↑ 26.1%
Over 6 Months
LowHigh
29.0243.50
↓ -12.0%
Over 1 Year
LowHigh
27.9649.99
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Financials

View full financials, peers & valuation multiples →
Revenue (Dec. 31, 2025)
₹16 Cr
Net profit (Dec. 31, 2025)
₹1 Cr
Basic EPS (Dec. 31, 2025)
₹0.9200

Ranks #145 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter5.98%
  • FII/FPI0.50%

Largest holders

NameCategoryShares %Shares
ARJUN AGGARWALPublic11.3500%2180000
GADDAM VENKATA RAMANAPromoter2.4600%471600
MADHU NALAJALAPublic2.4000%461439
RAJESH PODDARPublic2.1500%413256
PALLOLI RAMA CHANDRA REDDYPublic1.8600%356835

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 5.98% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 0.36% to 0.50% in Jun 2026 qtr

Historical mutual fund holding

All shareholding details →

Insider trading, SAST & pledges

All 96 insider trades, 16 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
18 Nov 2025 Alluri Maithili Promoter Sell 0 ₹0
18 Nov 2025 Satyanarayana Raju Bhupathiraju Promoter Sell 0 ₹0
18 Nov 2025 Alluri Anantha Laxmi Promoter Sell 0 ₹0
18 Nov 2025 Alluri Prabhakar Raju Promoter Sell 0 ₹0
18 Nov 2025 Gaddam Venkata Ramana Promoter Sell 0 ₹0
18 Nov 2025 Alluri Srinivasa Raju Promoter Sell 0 ₹0
18 Nov 2025 Pericharla Kishore Raju Promoter Sell 0 ₹0
18 Nov 2025 ALLURI RANGA RAJU Promoter Sell 0 ₹0
4 Oct 2025 Alluri Prabhakar Raju Promoter Sell 0 ₹0
4 Oct 2025 Gaddam Venkata Ramana Promoter Sell 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 97 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
29 Sep 2026 MANGAL KESHAV CAPITAL LIMITED Bulk Buy 800,000 36.7700 NSE
29 Sep 2026 ISWARYA GAJJALA Bulk Sell 291,000 36.7300 NSE
29 Sep 2026 MALLUKUNTLA LAKSHMIDEVI Bulk Sell 180,000 36.8400 NSE
1 Sep 2026 CHARAN REDDY PULI Bulk Buy 100,000 38.0500 NSE
1 Sep 2026 ANASUYA GORLA Bulk Sell 113,000 38.0400 NSE
21 Aug 2026 SUJATA KUMARI JHA Bulk Buy 109,870 37.7700 NSE
21 Aug 2026 ARJUN AGGARWAL Bulk Sell 110,587 37.8300 NSE
20 Jan 2026 VENKAITEELA MAANAS Bulk Buy 50,000 34.7500 NSE
20 Jan 2026 MOHAMMAD SALIM SHAIKH Bulk Buy 85,000 32.7200 NSE
20 Jan 2026 HJS SECURITIES PRIVATE LIMITED Bulk Sell 86,893 32.7100 NSE

All bulk and block deals →

Dividends

Full dividend history →
Ex-dateSubjectPer share (₹)Record date
19 Sep 2022 Dividend - Re 1 Per Share 1.0000 20 Sep 2022

Corporate Actions

Full history (5 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
23 Dec 2025RIGHTSRights 13:12 @ Premium Rs 20/-
17 Sep 2024OTHERAnnual General Meeting
18 Sep 2023OTHERAnnual General Meeting
22 Sep 2021OTHER Annual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
30 May 2026 Financial Results Yes
14 Feb 2026 Financial Results Yes
27 Nov 2025 Fund Raising —
8 Nov 2025 Financial Results Yes
23 Oct 2025 Board meeting Rescheduled —

Corporate Announcements

All 259 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
30 Sep 2026 Company Update Vineet Laboratories Ltd - 543298 - Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors
30 Sep 2026 Insider Trading / SAST Vineet Laboratories Ltd - 543298 - Closure of Trading Window
30 Sep 2026 Resignation Vineet Laboratories Limited has informed the Exchange regarding Resignation of NSVR & Associates LLP as of the company w.e.f. September 29, 2026.
30 Sep 2026 Trading Window Vineet Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
19 Sep 2026 Company Update Vineet Laboratories Ltd - 543298 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Grant Of Extension Of Time By The Registrar Of Companies For Holding The 10St Annual General Meeting Of The Company
19 Sep 2026 General Updates Vineet Laboratories Limited has informed the Exchange about General UpdatesSub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Grant of extension of time by the Registrar of Companies for holding the 10st Annual General Meeting of the Company We wish to inform you that the Registrar of Companies, Hyderabad ( ROC Hyderabad ), has granted an extension of two months for holding the 10th Annual General Meeting ( AGM ) of the Company in respect of the financial year ended 31st March, 2026.Accordingly, the Company has been granted an extension to hold the AGM up to 30th November, 2026. The approval letter in this regard was received from ROC Hyderabad on 18th September, 2026.A copy of the said approval order is enclosed.
8 Sep 2026 Clarification - Financial Results The Exchange has sought clarification from Vineet Laboratories Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Financial Results not submitted The response of the Company is awaited.
29 Aug 2026 General Updates Vineet Laboratories Limited has informed the Exchange about General Updates
25 Aug 2026 Outcome of Board Meeting Vineet Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
25 Aug 2026 Outcome of Board Meeting Vineet Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.The Board of Directors of the company in its meeting held today i.e., on August 25, 2026 has:Approved the Audited Standalone Financial Results of the Company for the fourth quarter and the financial year ended on 31 March, 2026 and the Audited Standalone Financial Statement for the financial year ended on 31* March 2026 along with Audit Report.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

Data unavailable.

Weaknesses

  • Low Return on Equity (-17.0%)
  • Thin net profit margin (-31.5%)
  • Declining revenue YoY (-13.5%)
  • Declining profit YoY (-176.2%)

Opportunities

Data unavailable.

Threats

  • Weak interest coverage (-1.3x) -- limited cushion against rising rates

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Vineet Laboratories Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.